vida: extract claims from 2025-12-phti-employer-glp1-coverage-market-report

- Source: inbox/queue/2025-12-phti-employer-glp1-coverage-market-report.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

@@ -9,12 +9,8 @@ title: Comprehensive behavioral wraparound may enable durable weight maintenance
 agent: vida
 scope: causal
 sourcer: Omada Health
-related:
-- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose
-- WeightWatchers Med+
-reweave_edges:
-- Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose|related|2026-04-14
-- WeightWatchers Med+|related|2026-04-17
+related: ["Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose", "WeightWatchers Med+", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two"]
+reweave_edges: ["Digital behavioral support combined with individualized GLP-1 dosing achieves clinical trial weight-loss outcomes with approximately half the standard drug dose|related|2026-04-14", "WeightWatchers Med+|related|2026-04-17"]
 ---
 
 # Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
@@ -23,4 +19,10 @@ The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1
 
 The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
 
-Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.
+Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.
+
+## Supporting Evidence
+
+**Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
+
+Employer payers are adopting tiered coverage models that bundle GLP-1 drugs with behavioral programs versus drug-only coverage. PHTI reports employers moving from 'cover the drug' to 'cover the drug + support program' to manage cost and outcomes. This payer adoption pattern validates the behavioral support necessity thesis—the market is making support programs a coverage requirement, not an optional add-on.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -30,3 +30,10 @@ Cost is a major driver of discontinuation: 14% of former GLP-1 users stopped due
 **Source:** Cell/Med 2025, The Societal Implications of Using GLP-1 Receptor Agonists for the Treatment of Obesity
 
 Cell/Med 2025 connects low persistence rates to the sustainability concern: chronic use model + high prices + discontinuation effects = fiscal unsustainability at scale. The paper notes need to 'consider acceptability over long term and implications for weight stigma,' suggesting that persistence barriers are not just clinical or financial but also social. The equity inversion compounds this: those with highest need face both highest discontinuation rates (per existing KB claims on wealth-stratified access) and lowest initial access, creating a double barrier to population-level impact.
+
+
+## Extending Evidence
+
+**Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
+
+PHTI December 2025 report documents employer payer response to low GLP-1 persistence: movement toward bundled coverage requiring behavioral support programs as a condition of drug coverage. Employers are framing GLP-1 coverage without personal support as 'wasted wellness dollars' (Benefits Pro, March 2026). This represents the market mechanism translating adherence data into coverage architecture—payers are structurally responding to the persistence problem by mandating behavioral wraparound rather than covering drugs alone.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
 
 ICER's April 2025 white paper documents that self-insured employers offering GLP-1 obesity coverage experienced >10x increase in per-member, per-month (PMPM) costs from January 2023 to December 2024. Blue Cross Blue Shield of Massachusetts ended 2024 with a $400 million operating loss, with GLP-1 drugs identified as 'the single largest driver,' accounting for >$300 million in 2024 alone. This is a more acute cost curve than California's Medi-Cal trajectory ($85M → $680M projected over 4 years, ~8x increase), suggesting employer plan costs are escalating faster than state Medicaid programs. The BCBS MA datum provides the concrete mechanism for why states like California, New Hampshire, Pennsylvania, and South Carolina eliminated Medi-Cal coverage: the cost trajectory threatens plan solvency. This is not ideological opposition or negligent policy—it's structurally forced by fiscal reality. ICER's focus on 'payer sustainability strategies' rather than access expansion reflects the structural tension: even the most rigorous health economics organization is working on how to contain access, not expand it. The National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' which itself reveals the zero-sum nature of the access-sustainability trade-off under current financing structures.
+
+
+## Extending Evidence
+
+**Source:** PHTI Employer GLP-1 Coverage Market Trend Report, December 2025
+
+Employer response to GLP-1 cost pressure includes cost management strategies: step therapy, prior authorization, and lifestyle program requirements as coverage conditions. PHTI documents employers adopting 'scalable tech-enabled care with measurable outcomes' as the winning strategy in a 'high-pressure environment.' This shows payers are not simply cutting coverage but restructuring it around adherence and outcomes infrastructure to manage the fiscal burden.

entities/health/peterson-health-technology-institute.md

@@ -0,0 +1,32 @@
+---
+title: Peterson Health Technology Institute (PHTI)
+entity_type: organization
+domain: health
+status: active
+---
+
+# Peterson Health Technology Institute (PHTI)
+
+Nonprofit health technology assessment organization that evaluates digital health and clinical tools for payers and employers.
+
+## Overview
+
+PHTI conducts independent assessments of health technology value, focusing on evidence-based evaluation for employer and payer decision-making. Not industry-funded; has assessed GLP-1s skeptically in prior work.
+
+## Key Activities
+
+- Health technology assessment for payer/employer audiences
+- Market trend analysis of coverage decisions
+- Evidence synthesis for digital health and pharmaceutical interventions
+
+## Timeline
+
+- **2025-12** — Published market trend report on employer approaches to GLP-1 coverage, documenting shift toward bundled drug + behavioral support coverage models
+
+## Significance
+
+PHTI's documentation of employer coverage patterns provides credible market signal data on payer decision-making, particularly valuable because of their independent (non-industry-funded) positioning.
+
+## Sources
+
+- PHTI Employer Approaches to GLP-1 Coverage Market Trend Report (December 2025)

inbox/archive/health/2025-12-phti-employer-glp1-coverage-market-report.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: industry-research
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-27
 priority: medium
 tags: [glp-1, employer-coverage, payer, benefits, cost-management, adherence, value-based-care, obesity]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content